MemoDero

Treating Fear-related Disorders

Health Tech & Life Sciences
Non Active, Feb 2022 ceased to operate
Seed Haifa, Israel Founded 2015
Website ↗
Last updated 2026-06-18
Total raised
Last: 2015-01
Stage
Seed
Founded
2015
Headcount
6
HQ
Haifa, Israel
Sector
Health Tech & Life Sciences

About

MemoDero is developing a first-in-class drug candidate to prevent debilitating consequences of fear-related diseases, such as post-traumatic stress disorder. The company's team is currently in the advanced stages of developing and evaluating the drug pep-EphrinA4, aimed at reducing or preventing the debilitating consequences of fearful memories. The drug is intended to inhibit the development of a fear memory following a traumatic event.

Funding history · 1 round · — total

2015-01

Q&A

What is MemoDero's primary focus?
MemoDero is developing a first-in-class drug candidate to prevent the debilitating consequences of fear-related diseases, such as post-traumatic stress disorder.
What is the status of MemoDero?
MemoDero is currently inactive, having ceased operations in February 2022.
When was MemoDero founded?
MemoDero was founded in January 2015.
What drug candidate is MemoDero developing?
MemoDero is in advanced stages of developing and evaluating the drug pep-EphrinA4, which is intended to inhibit the development of fear memory following a traumatic event.
How many employees did MemoDero have?
MemoDero had an employee count in the 1-10 range.
Who was a key founder of MemoDero?
Prof. Raphael Lamprecht was a Scientific Founder of MemoDero.
What was MemoDero's primary sector?
MemoDero's primary sector was Health Tech & Life Sciences.
Which investor participated in MemoDero's funding round?
Carmel Innovation Fund participated in MemoDero's funding round in January 2015.

Team · 1

Founder · Scientific Founder
LinkedIn ↗

Sectors & technology

Primary sector
Health Tech & Life Sciences
Sub-sectors
Health Tech & Life SciencesPharma & Medical BiotechnologyDrugs Discovery & Development
Technologies
Biologicals
Target customers
Healthcare & Life SciencesLife SciencesPharmaceuticals
Business model
B2B

Tags

pharmaceuticalspatent-pendingmental-healthpharma-companiespatients
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)